Overview

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Status:
Completed
Trial end date:
2015-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, two-group, fixed-sequence study to evaluate the effect of ACH-3102 and Simeprevir on AL-335 pharmacokinetics in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Alios Biopharma Inc.
Collaborators:
Achillion Pharmaceuticals
Alexion Pharmaceuticals
Treatments:
Odalasvir
Simeprevir